In-Vivo CAR-T for Systemic Autoimmunity: Emerging Paradigms and Clinical Implications

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy has rapidly evolved from its origins in oncology to become a promising modality in the management of systemic autoimmune diseases. In-vivo CAR-T, wherein genetically engineered T cells are generated directly within the patient, offers a transformative approach to modulate immune dysregulation without the logistical complexities and risks associated with ex-vivo cell manufacturing. This review synthesizes the latest evidence on the application of in-vivo CAR-T for systemic autoimmunity, discussing mechanistic rationale, clinical outcomes, safety considerations, and future directions relevant to the care of patients with refractory autoimmune conditions.

Introduction

Systemic autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS) are characterized by aberrant immune responses leading to multiorgan injury and chronic morbidity. Despite advances in immunomodulatory therapies, a significant subset of patients remain refractory to existing treatments. CAR-T cell therapies, initially designed for hematologic malignancies, have demonstrated the capacity to selectively target pathogenic immune cell populations. The advent of in-vivo CAR-T—where gene editing tools and viral/nonviral vectors are used to engineer T cells within the patient—has generated substantial interest as a scalable, potentially safer alternative to traditional ex-vivo approaches for systemic autoimmune disorders.

Epidemiology / Disease Burden

Systemic autoimmune diseases collectively affect millions worldwide, with a disproportionate impact on women and younger populations. SLE, for example, has an estimated prevalence of 20–150 cases per 100,000 individuals, with significant geographical and ethnic variation. These diseases are associated with substantial morbidity, increased healthcare utilization, and, in some cases, early mortality. Conventional therapies may induce remission in many, yet long-term steroid exposure and immunosuppressants carry risks of infection, malignancy, and organ toxicity, underscoring the need for targeted, durable, and less toxic interventions.

Pathophysiology

The pathogenesis of systemic autoimmunity involves a complex interplay between genetic predisposition, environmental triggers, and immune dysregulation. Central to disease progression is the breakdown of self-tolerance, resulting in the expansion of autoreactive B and T lymphocytes. Autoreactive B cells generate pathogenic autoantibodies and contribute to immune complex formation, while dysregulated T cells provide aberrant help, perpetuate inflammation, and drive tissue damage. Current immunotherapies broadly suppress immune activity, but fail to specifically eliminate disease-driving cell populations. CAR-T therapy offers the prospect of precise, antigen-directed depletion of autoreactive clones, addressing the root cause of autoimmunity.

Risk Factors

Both genetic and environmental factors contribute to the development and progression of systemic autoimmune diseases. Genetic susceptibility loci, such as HLA-DRB1 and PTPN22, are implicated in the risk of RA and SLE. Environmental triggers include infections, hormonal influences, ultraviolet radiation, and smoking. Treatment resistance is often associated with disease chronicity, high disease activity, and certain autoantibody profiles. Understanding these risk factors is critical for identifying patients most likely to benefit from novel therapeutics such as in-vivo CAR-T.

Clinical Features

Systemic autoimmune diseases present with diverse clinical manifestations reflecting their multisystem involvement. Common features include constitutional symptoms (fatigue, fever), joint and muscle pain, cutaneous lesions, serositis, renal dysfunction, and neuropsychiatric symptoms. The presence of specific autoantibodies, such as anti-dsDNA in SLE or anti-CCP in RA, aids in diagnosis and prognostication. Disease flares and chronicity contribute to cumulative organ damage, reduced quality of life, and increased mortality risk, particularly in patients with refractory disease.

Diagnosis

Diagnosis of systemic autoimmunity relies on a combination of clinical findings, serologic markers, and, where indicated, tissue biopsy. The classification criteria for diseases like SLE and RA integrate major organ involvement, antibody profiles, and laboratory abnormalities. Disease activity indices (e.g., SLEDAI, DAS28) are routinely used to monitor progression and therapeutic response. Emerging biomarkers, such as cell-free DNA and immune repertoire analysis, may enhance early detection and help identify patients with persistent autoreactivity suitable for CAR-T intervention.

Treatment & Management

Conventional management of systemic autoimmunity includes corticosteroids, antimalarials (e.g., hydroxychloroquine), disease-modifying antirheumatic drugs (DMARDs), and biologics targeting cytokines or B cells (e.g., anti-TNF, anti-CD20). Despite these advances, many patients experience incomplete remission or intolerable adverse effects. Hematopoietic stem cell transplantation (HSCT) has been explored for refractory cases but is limited by significant toxicity. The development of in-vivo CAR-T therapy, targeting B cell antigens such as CD19, allows direct inactivation or depletion of autoreactive B cells, potentially inducing durable remission without the need for ongoing immunosuppression.

Recent Advances / Emerging Therapies

Recent preclinical and early-phase clinical studies have demonstrated that in-vivo CAR-T targeting CD19 can effectively deplete pathogenic B cells and ameliorate disease activity in models of SLE and other systemic autoimmune conditions. Advances in gene editing, such as CRISPR/Cas9 and nonviral delivery platforms, have improved the safety and efficiency of in-vivo CAR-T generation. Notably, the avoidance of ex-vivo cell manipulation reduces manufacturing time, cost, and the risk of contamination or cellular exhaustion. Ongoing trials are assessing novel CAR constructs directed at alternative targets, such as CD20 and BCMA, and exploring strategies to enhance persistence, reduce off-target effects, and minimize cytokine release syndrome (CRS).

Guideline Recommendations

Current guidelines from rheumatology and immunology societies do not yet incorporate in-vivo CAR-T therapy into standard care pathways, reflecting its investigational status. However, expert consensus emphasizes the need for rigorous patient selection, with a focus on those with severe, refractory disease unresponsive to approved therapies. Safety monitoring for infections, secondary malignancy, and immune reconstitution is paramount, and multidisciplinary collaboration is advised to optimize outcomes. As clinical trial data mature, formal guideline recommendations are anticipated to evolve.

Conclusion

In-vivo CAR-T therapy represents a frontier in the management of systemic autoimmunity, offering the promise of antigen-specific, durable immune modulation with reduced procedural complexity. While early results are encouraging, robust clinical trials are needed to establish long-term efficacy, safety, and optimal patient selection criteria. As the field advances, in-vivo CAR-T may become a cornerstone of precision immunotherapy for patients with refractory systemic autoimmune diseases, fundamentally transforming the therapeutic landscape and improving patient outcomes.